Literature DB >> 10807655

Acute blood pressure effects of YC-1-induced activation of soluble guanylyl cyclase in normotensive and hypertensive rats.

L Rothermund1, A Friebe, M Paul, D Koesling, R Kreutz.   

Abstract

We used YC-1 as a pharmacological tool to investigate the short-term blood pressure effects of NO-independent activation of sGC in normotensive and hypertensive rats. Four groups of normotensive Wistar-Kyoto rats were treated by i.v. injection with vehicle (V), YC-1 (YC-1), sodium nitroprusside (SNP), or YC-1 and SNP (YC-1+SNP). Hypertension was induced in four additional groups of WKY rats by 3 weeks of oral treatment with L-NAME. These animals were investigated with the same protocol as the normotensive animals: L-NAME/V, L-NAME/YC-1, L-NAME/SNP, L-NAME/YC-1+SNP. YC-1 lowered mean arterial blood pressure (MAP) in normotensive and hypertensive animals similarly to SNP alone (P<0.05, respectively). The combination of YC-1 with SNP caused a strong decrease of MAP in both the hypertensive and normotensive animals (P<0.05, respectively). SNP with YC-1 also induced a pronounced cyclic GMP increase in the aorta. This study shows for the first time the blood pressure lowering potential of bimodal targeting of the NO-sGC-system.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10807655      PMCID: PMC1572080          DOI: 10.1038/sj.bjp.0703320

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  14 in total

Review 1.  Radioimmunoassay of cyclic AMP and cyclic GMP.

Authors:  G Brooker; J F Harper; W L Terasaki; R D Moylan
Journal:  Adv Cyclic Nucleotide Res       Date:  1979

2.  Development and mechanism of a specific supersensitivity to nitrovasodilators after inhibition of vascular nitric oxide synthesis in vivo.

Authors:  S Moncada; D D Rees; R Schulz; R M Palmer
Journal:  Proc Natl Acad Sci U S A       Date:  1991-03-15       Impact factor: 11.205

3.  YC-1, a novel activator of platelet guanylate cyclase.

Authors:  F N Ko; C C Wu; S C Kuo; F Y Lee; C M Teng
Journal:  Blood       Date:  1994-12-15       Impact factor: 22.113

4.  Sensitizing soluble guanylyl cyclase to become a highly CO-sensitive enzyme.

Authors:  A Friebe; G Schultz; D Koesling
Journal:  EMBO J       Date:  1996-12-16       Impact factor: 11.598

5.  Activation of soluble splenic cell guanylate cyclase by prostaglandin endoperoxides and fatty acid hydroperoxides.

Authors:  G Graff; J H Stephenson; D B Glass; M K Haddox; N D Goldberg
Journal:  J Biol Chem       Date:  1978-11-10       Impact factor: 5.157

6.  Effect of YC-1, an NO-independent, superoxide-sensitive stimulator of soluble guanylyl cyclase, on smooth muscle responsiveness to nitrovasodilators.

Authors:  A Mülsch; J Bauersachs; A Schäfer; J P Stasch; R Kast; R Busse
Journal:  Br J Pharmacol       Date:  1997-02       Impact factor: 8.739

7.  YC-1, a nitric oxide-independent activator of soluble guanylate cyclase, inhibits platelet-rich thrombosis in mice.

Authors:  C M Teng; C C Wu; F N Ko; F Y Lee; S C Kuo
Journal:  Eur J Pharmacol       Date:  1997-02-12       Impact factor: 4.432

8.  Mechanism of YC-1-induced activation of soluble guanylyl cyclase.

Authors:  A Friebe; D Koesling
Journal:  Mol Pharmacol       Date:  1998-01       Impact factor: 4.436

9.  Activation of purified soluble guanylate cyclase by protoporphyrin IX.

Authors:  L J Ignarro; K S Wood; M S Wolin
Journal:  Proc Natl Acad Sci U S A       Date:  1982-05       Impact factor: 11.205

10.  YC-1 potentiates nitric oxide- and carbon monoxide-induced cyclic GMP effects in human platelets.

Authors:  A Friebe; F Müllershausen; A Smolenski; U Walter; G Schultz; D Koesling
Journal:  Mol Pharmacol       Date:  1998-12       Impact factor: 4.436

View more
  13 in total

1.  Soluble guanylate cyclase: an old therapeutic target re-visited.

Authors:  Adrian J Hobbs
Journal:  Br J Pharmacol       Date:  2002-07       Impact factor: 8.739

Review 2.  NO-independent stimulators and activators of soluble guanylate cyclase: discovery and therapeutic potential.

Authors:  Oleg V Evgenov; Pál Pacher; Peter M Schmidt; György Haskó; Harald H H W Schmidt; Johannes-Peter Stasch
Journal:  Nat Rev Drug Discov       Date:  2006-09       Impact factor: 84.694

3.  YC-1 activation of human soluble guanylyl cyclase has both heme-dependent and heme-independent components.

Authors:  E Martin; Y C Lee; F Murad
Journal:  Proc Natl Acad Sci U S A       Date:  2001-10-30       Impact factor: 11.205

Review 4.  Heme-dependent and independent soluble guanylate cyclase activators and vasodilation.

Authors:  Fernanda B M Priviero; R Clinton Webb
Journal:  J Cardiovasc Pharmacol       Date:  2010-09       Impact factor: 3.105

Review 5.  Soluble guanylate cyclase as an emerging therapeutic target in cardiopulmonary disease.

Authors:  Johannes-Peter Stasch; Pál Pacher; Oleg V Evgenov
Journal:  Circulation       Date:  2011-05-24       Impact factor: 29.690

6.  YC-1 attenuates LPS-induced proinflammatory responses and activation of nuclear factor-kappaB in microglia.

Authors:  D-Y Lu; C-H Tang; H-C Liou; C-M Teng; K-C G Jeng; S-C Kuo; F-Y Lee; W-M Fu
Journal:  Br J Pharmacol       Date:  2007-04-02       Impact factor: 8.739

7.  Cardiovascular actions of a novel NO-independent guanylyl cyclase stimulator, BAY 41-8543: in vivo studies.

Authors:  Johannes-Peter Stasch; Klaus Dembowsky; Elisabeth Perzborn; Elke Stahl; Matthias Schramm
Journal:  Br J Pharmacol       Date:  2002-01       Impact factor: 8.739

8.  CCAAT-binding factor regulates expression of the beta1 subunit of soluble guanylyl cyclase gene in the BE2 human neuroblastoma cell line.

Authors:  Iraida G Sharina; Emil Martin; Anthony Thomas; Karen L Uray; Ferid Murad
Journal:  Proc Natl Acad Sci U S A       Date:  2003-09-22       Impact factor: 11.205

9.  YC-1 stimulates the expression of gaseous monoxide-generating enzymes in vascular smooth muscle cells.

Authors:  Xiao-Ming Liu; Kelly J Peyton; Natalia N Mendelev; Hong Wang; David A Tulis; William Durante
Journal:  Mol Pharmacol       Date:  2008-10-15       Impact factor: 4.436

Review 10.  Cyclic GMP signaling in cardiovascular pathophysiology and therapeutics.

Authors:  Emily J Tsai; David A Kass
Journal:  Pharmacol Ther       Date:  2009-03-21       Impact factor: 12.310

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.